1. A blade head assembly for a hand-held hair cutting appliance, the hair cutting appliance comprising a handle, a drive assembly disposed at least in part within the handle and held in assembly therewith, and the blade head assembly, said blade head assembly being removably attachable to the handle in operative connection with the drive assembly and comprising:
a blade head assembly housing having a front, a back and two opposite sides,
a first cutting blade and a second cutting blade, said first and second cutting blades being held in assembly with the blade head assembly housing for attachment and detachment from the handle with the blade head assembly, said first cutting blade being capable of reciprocating translational movement relative to the blade head assembly housing such that the first cutting blade is moveable in a side to side direction relative to the handle and the second cutting blade, the blade head assembly being arranged and configured such that upon attachment of the blade head assembly to the handle of the hair cutting appliance the first cutting blade is operatively connected to the drive assembly; and
a counter weight held in assembly with the blade head assembly housing and being adapted for reciprocating movement relative thereto in response to reciprocating translational movement of the first cutting blade to thereby at least partially counter-balance the reciprocating translational movement of the first cutting blade, the blade head assembly being configured for movement of the counter weight in a direction generally opposite to a direction of movement of the first cutting blade.
2. The blade head assembly set forth in claim 1 wherein the counter weight is held in assembly with the first cutting blade for conjoint operative connection of the first cutting blade and the counter weight with the drive assembly upon attachment of the blade head assembly to the handle of the hair cutting appliance.
3. The blade head assembly set forth in claim 2 further comprising a pivot link pivotably connected to the housing for pivoting movement relative thereto about a pivot axis oriented other than in the direction of reciprocation of the first cutting blade, the pivot link being adapted for operative connection to the drive assembly upon attachment of the blade head assembly to the handle of the hair cutting appliance such that the drive assembly reciprocatingly pivots the pivot link about its pivot axis, the first cutting blade and the counter weight each being operatively connected to the pivot link in spaced relationship with the pivot axis such that the pivot link conjointly reciprocates the first cutting blade and the counter weight in response to the pivot link being reciprocatingly pivoted by the drive assembly.
4. The blade head assembly set forth in claim 3 wherein the first cutting blade and the counter weight are arranged relative to the pivot link in operative connection therewith such that the counter weight continually moves in a direction generally opposite to the direction in which the first cutting blade moves upon reciprocating pivoting movement of the pivot link about its pivot axis.
5. The blade head assembly set forth in claim 4 wherein the pivot link is generally elongate and has a longitudinal axis, a first segment extending longitudinally away from the pivot axis on said longitudinal axis and a second segment extending longitudinally away from the pivot axis on said longitudinal axis in a direction opposite the first segment, the first cutting blade being held in assembly with the first segment and the counter weight being held in assembly with the second segment.
6. The blade head assembly set forth in claim 4 wherein first cutting blade, the pivot link and the counter weight together have a center of mass, said center of mass being one of at and adjacent to the pivot axis of the pivot link.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A crystalline form of lamivudine hydrochloride.
2. The crystalline form of lamivudine hydrochloride of claim 1, wherein the crystalline form of lamivudine hydrochloride is lamivudine hydrochloride polymorph Form I.
3. The crystalline form of lamivudine hydrochloride of any of claims 1-2, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine hydrochloride comprises peaks with degrees 2\u03b8 values of 14.7\xb10.3, 22.7\xb10.3, 23.1\xb10.3, and 24.9\xb10.3.
4. The crystalline form of lamivudine hydrochloride of claim 3, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine hydrochloride further comprises peaks with degrees 2\u03b8 values of 28.0\xb10.3 and 31.1\xb10.3.
5. The crystalline form of lamivudine hydrochloride of claim 4, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine hydrochloride further comprises peaks with degrees 2\u03b8 values of 31.8\xb10.3 and 32.2\xb10.3.
6. The crystalline form of lamivudine hydrochloride of any of claims 2-5, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine hydrochloride comprises at least five peaks with degrees 2\u03b8 values selected from the group consisting of 13.2\xb10.3, 14.7\xb10.3, 14.8\xb10.3, 17.6\xb10.3, 18.3\xb10.3, 18.5\xb10.3, 21.7\xb10.3, 22.7\xb10.3, 23.1\xb10.3, 23.7\xb10.3, 24.9\xb10.3, 27.4\xb10.3, 28.0\xb10.3, 30.3\xb10.3, 31.1\xb10.3, 31.3\xb10.3, 31.4\xb10.3, 31.8\xb10.3, 32.2\xb10.3, 32.8\xb10.3, 33.1\xb10.3, 33.9\xb10.3, 34.8\xb10.3, 36.3\xb10.3, and 39.1\xb10.3.
7. The crystalline form of lamivudine hydrochloride of any of claims 2-6, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine hydrochloride comprises at least 10 peaks with degrees 2\u03b8 values selected from the group consisting of 13.2\xb10.3, 14.7\xb10.3, 14.8\xb10.3, 17.6\xb10.3, 18.3\xb10.3, 18.5\xb10.3, 21.7\xb10.3, 22.7\xb10.3, 23.1\xb10.3, 23.7\xb10.3, 24.9\xb10.3, 27.4\xb10.3, 28.0\xb10.3, 30.3\xb10.3, 31.1\xb10.3, 31.3\xb10.3, 31.4\xb10.3, 31.8\xb10.3, 32.2\xb10.3, 32.8\xb10.3, 33.1\xb10.3, 33.9\xb10.3, 34.8\xb10.3, 36.3\xb10.3, and 39.1\xb10.3.
8. The crystalline form of lamivudine hydrochloride of any of claims 2-7, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine hydrochloride comprises at least 20 peaks with degrees 2\u03b8 values selected from the group consisting of 13.2\xb10.3, 14.7\xb10.3, 14.8\xb10.3, 17.6\xb10.3, 18.3\xb10.3, 18.5\xb10.3, 21.7\xb10.3, 22.7\xb10.3, 23.1\xb10.3, 23.7\xb10.3, 24.9\xb10.3, 27.4\xb10.3, 28.0\xb10.3, 30.3\xb10.3, 31.1\xb10.3, 31.3\xb10.3, 31.4\xb10.3, 31.8\xb10.3, 32.2\xb10.3, 32.8\xb10.3, 33.1\xb10.3, 33.9\xb10.3, 34.8\xb10.3, 36.3\xb10.3, and 39.1\xb10.3.
9. The crystalline form of lamivudine hydrochloride of any of claims 2-8, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine hydrochloride comprises peaks with degrees 2\u03b8 values of 13.2\xb10.3, 14.7\xb10.3, 14.8\xb10.3, 17.6\xb10.3, 18.3\xb10.3, 18.5\xb10.3, 21.7\xb10.3, 22.7\xb10.3, 23.1\xb10.3, 23.7\xb10.3, 24.9\xb10.3, 27.4\xb10.3, 28.0\xb10.3, 30.3\xb10.3, 31.1\xb10.3, 31.3\xb10.3, 31.4\xb10.3, 31.8\xb10.3, 32.2\xb10.3, 32.8\xb10.3, 33.1\xb10.3, 33.9\xb10.3, 34.8\xb10.3, 36.3\xb10.3, and 39.1\xb10.3.
10. The crystalline form of lamivudine hydrochloride of any of claims 2-9 having an X-ray powder diffraction pattern substantially the same as that shown in FIG. 6.
11. The crystalline form of lamivudine hydrochloride of any of claims 2-10, which exhibits a Raman spectrum comprising peaks at wave number values of about 781\xb15 and 1671\xb15.
12. The crystalline form of lamivudine hydrochloride of claim 11, which exhibits a Raman spectrum further comprising peaks at wave number values of about 285\xb15, 376\xb15, 501\xb15, 550\xb15, 604\xb15, 660\xb15, 708\xb15, 995\xb15, 1133\xb15, 1174\xb15, 1360\xb15, 1425\xb15, 1535\xb15, and 1611\xb15.
13. The crystalline form of lamivudine hydrochloride of any of claims 2-12, which exhibits a Differential Scanning Calorimetry thermogram comprising an endotherm with an onset of about 197.8\xb10.5\xb0 C. to about 200.6\xb10.5\xb0 C. for a scan rate of about 10\xb0 C.minute.
14. The crystalline form of lamivudine hydrochloride of any of claims 2-13, which exhibits a Differential Scanning Calorimetry thermogram having a single endotherm with an onset of about 197.8\xb10.5\xb0 C. to about 200.6\xb10.5\xb0 C. for a scan rate of about 10\xb0 C.minute.
15. The crystalline form of lamivudine hydrochloride of any of claims 2-14, which exhibits a weight gain of about 1.0% or less by Gravimetric Vapor Sorption conducted at 25\xb0 C. from 0% relative humidity to 90% relative humidity.
16. The crystalline form of lamivudine hydrochloride of any of claims 2-15, which is neither hydrated nor solvated.
17. The crystalline form of lamivudine hydrochloride of any of claims 1-16, wherein the lamivudine hydrochloride is a mono-hydrochloride.
18. The crystalline form of lamivudine hydrochloride of claim 1, wherein the crystalline form of lamivudine hydrochloride is lamivudine hydrochloride polymorph Form II.
19. The crystalline form of lamivudine hydrochloride of any of claim 1 or 18, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine hydrochloride comprises peaks with degrees 2\u03b8 values of 13.8\xb10.3, 14.0\xb10.3, and 31.1\xb10.3.
20. The crystalline form of lamivudine hydrochloride of claim 19, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine hydrochloride further comprises peaks with degrees 2\u03b8 values of 22.6\xb10.3 and 28.1\xb10.3.
21. The crystalline form of lamivudine hydrochloride of claim 20, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine hydrochloride further comprises peaks with degrees 2\u03b8 values of 33.9\xb10.3, and 36.5\xb10.3.
22. The crystalline form of lamivudine hydrochloride of any of claim 1 or 18-21, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine hydrochloride comprises at least five peaks with degrees 2\u03b8 values selected from the group consisting of 12.8\xb10.3, 13.8\xb10.3, 14.0\xb10.3, 14.5\xb10.3, 14.7\xb10.3, 16.5\xb10.3, 17.5\xb10.3, 18.3\xb10.3, 21.8\xb10.3, 22.6\xb10.3, 23.0\xb10.3, 23.1\xb10.3, 24.3\xb10.3, 24.8\xb10.3, 26.1\xb10.3, 26.6\xb10.3, 28.1\xb10.3, 30.3\xb10.3, 31.1\xb10.3, 32.3\xb10.3, 33.9\xb10.3, 36.3\xb10.3, 36.5\xb10.3, 38.4\xb10.3, and 39.1\xb10.3.
23. The crystalline form of lamivudine hydrochloride of any of claim 1 or 18-22, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine hydrochloride comprises at least 10 peaks with degrees 2\u03b8 values selected from the group consisting of 12.8\xb10.3, 13.8\xb10.3, 14.0\xb10.3, 14.5\xb10.3, 14.7\xb10.3, 16.5\xb10.3, 17.5\xb10.3, 18.3\xb10.3, 21.8\xb10.3, 22.6\xb10.3, 23.0\xb10.3, 23.1\xb10.3, 24.3\xb10.3, 24.8\xb10.3, 26.1\xb10.3, 26.6\xb10.3, 28.1\xb10.3, 30.3\xb10.3, 31.1\xb10.3, 32.3\xb10.3, 33.9\xb10.3, 36.3\xb10.3, 36.5\xb10.3, 38.4\xb10.3, and 39.1\xb10.3.
24. The crystalline form of lamivudine hydrochloride of any of claim 1 or 18-23, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine hydrochloride comprises at least 20 peaks with degrees 2\u03b8 values selected from the group consisting of 12.8\xb10.3, 13.8\xb10.3, 14.0\xb10.3, 14.5\xb10.3, 14.7\xb10.3, 16.5\xb10.3, 17.5\xb10.3, 18.3\xb10.3, 21.8\xb10.3, 22.6\xb10.3, 23.0\xb10.3, 23.1\xb10.3, 24.3\xb10.3, 24.8\xb10.3, 26.1\xb10.3, 26.6\xb10.3, 28.1\xb10.3, 30.3\xb10.3, 31.1\xb10.3, 32.3\xb10.3, 33.9\xb10.3, 36.3\xb10.3, 36.5\xb10.3, 38.4\xb10.3, and 39.1\xb10.3.
25. The crystalline form of lamivudine hydrochloride of any of claim 1 or 18-24, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine hydrochloride comprises peaks with degrees 2\u03b8 values of 12.8\xb10.3, 13.8\xb10.3, 14.0\xb10.3, 14.5\xb10.3, 14.7\xb10.3, 16.5\xb10.3, 17.5\xb10.3, 18.3\xb10.3, 21.8\xb10.3, 22.6\xb10.3, 23.0\xb10.3, 23.1\xb10.3, 24.3\xb10.3, 24.8\xb10.3, 26.1\xb10.3, 26.6\xb10.3, 28.1\xb10.3, 30.3\xb10.3, 31.1\xb10.3, 32.3\xb10.3, 33.9\xb10.3, 36.3\xb10.3, 36.5\xb10.3, 38.4\xb10.3, and 39.1\xb10.3.
26. The crystalline form of lamivudine hydrochloride of any of claim 1 or 18-25 having an X-ray powder diffraction pattern substantially the same as that shown in FIG. 12.
27. The crystalline form of lamivudine hydrochloride of any of claim 1 or 18-26, which exhibits a Differential Scanning Calorimetry thermogram comprising an endotherm with an onset of about 203.3\xb10.5\xb0 C. for a scan rate of about 10\xb0 C.minute.
28. The crystalline form of lamivudine hydrochloride of any of claim 1 or 18-27, which exhibits a Differential Scanning Calorimetry thermogram having a single endotherm with an onset of about 203.3\xb10.5\xb0 C. for a scan rate of about 10\xb0 C.minute.
29. The crystalline form of lamivudine hydrochloride of any of claim 1 or 18-28, which is neither hydrated nor solvated.
30. The crystalline form of lamivudine hydrochloride of any of claim 1 or 18-29, which is a mono-hydrochloride.
31. A method of making a crystalline form of lamivudine hydrochloride of any of claims 1-30, comprising:
suspending lamivudine in a non-solvent to form a suspension;
adding hydrochloric acid to the suspension; and
optionally heating the suspension to an elevated temperature.
32. The method of claim 31, further comprising, after heating the suspension:
cooling the suspension to a cooling temperature.
33. The method of claim 32, wherein the steps of heating the suspension and cooling the suspension comprise repeating the heating and cooling steps for about 6 hours to about 24 hours.
34. A method of making a crystalline form of lamivudine hydrochloride of any of claims 1-30, comprising:
dissolving lamivudine in a solvent to form a solution;
adding hydrochloric acid to the solution; and
optionally heating the solution to an elevated temperature.
35. The method of claim 34, further comprising, after heating the suspension:
cooling the solution to a cooling temperature.
36. The method of claim 35, wherein the steps of heating the suspension and cooling the suspension comprise repeating the heating and cooling steps for about 6 hours to about 24 hours.
37. A method of making lamivudine hydrochloride polymorph Form I comprising at least one of:
suspending lamivudine hydrochloride in a non-solvent; and
dissolving lamivudine hydrochloride in a solvent, to convert the lamivudine hydrochloride into lamivudine hydrochloride polymorph Form I.
38. The method of claim 37, wherein the lamivudine hydrochloride is amorphous lamivudine hydrochloride or crystalline lamivudine hydrochloride.
39. The method of any of claims 37-38, wherein the lamivudine hydrochloride is anhydrous crystalline lamivudine hydrochloride, hydrated crystalline lamivudine hydrochloride, or solvated crystalline lamivudine hydrochloride.
40. The method of any of claims 37-39, wherein the lamivudine hydrochloride is lamivudine hydrochloride polymorph Form II.
41. A crystalline form of lamivudine sulfate.
42. The crystalline form of lamivudine sulfate of claim 41, wherein the crystalline form of lamivudine sulfate is lamivudine sulfate polymorph Form I.
43. The crystalline form of lamivudine sulfate of any of claims 41-42, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine sulfate comprises peaks with degrees 2\u03b8 values of 20.2\xb10.3, 21.7\xb10.3, and 24.1\xb10.3.
44. The crystalline form of lamivudine sulfate of claim 43, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine sulfate further comprises peaks with degrees 2\u03b8 values of 16.0\xb10.3 and 19.0\xb10.3.
45. The crystalline form of lamivudine sulfate of claim 44, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine sulfate further comprises peaks with degrees 2\u03b8 values of 27.0\xb10.3 and 30.8\xb10.3.
46. The crystalline form of lamivudine sulfate of any of claims 41-45, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine sulfate comprises at least five peaks with degrees 2\u03b8 values selected from the group consisting of 9.8\xb10.3, 10.3\xb10.3, 14.0\xb10.3, 14.5\xb10.3, 14.7\xb10.3, 15.4\xb10.3, 16.0\xb10.3, 16.4\xb10.3, 17.0\xb10.3, 19.0\xb10.3, 19.6\xb10.3, 20.2\xb10.3, 20.7\xb10.3, 21.4\xb10.3, 21.7\xb10.3, 22.5\xb10.3, 23.1\xb10.3, 24.1\xb10.3, 24.6\xb10.3, 24.9\xb10.3, 26.4\xb10.3, 27.0\xb10.3, 27.4\xb10.3, 27.9\xb10.3, 28.2\xb10.3, 29.5\xb10.3, 30.0\xb10.3, 30.3\xb10.3, 30.8\xb10.3, 31.8\xb10.3, 32.1\xb10.3, 32.6\xb10.3, 33.8\xb10.3, 35.0\xb10.3, 35.6\xb10.3, 36.4\xb10.3, 37.6\xb10.3, and 38.0\xb10.3.
47. The crystalline form of lamivudine sulfate of any of claims 41-46, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine sulfate comprises at least 10 peaks with degrees 2\u03b8 values selected from the group consisting of 9.8\xb10.3, 10.3\xb10.3, 14.0\xb10.3, 14.5\xb10.3, 14.7\xb10.3, 15.4\xb10.3, 16.0\xb10.3, 16.4\xb10.3, 17.0\xb10.3, 19.0\xb10.3, 19.6\xb10.3, 20.2\xb10.3, 20.7\xb10.3, 21.4\xb10.3, 21.7\xb10.3, 22.5\xb10.3, 23.1\xb10.3, 24.1\xb10.3, 24.6\xb10.3, 24.9\xb10.3, 26.4\xb10.3, 27.0\xb10.3, 27.4\xb10.3, 27.9\xb10.3, 28.2\xb10.3, 29.5\xb10.3, 30.0\xb10.3, 30.3\xb10.3, 30.8\xb10.3, 31.8\xb10.3, 32.1\xb10.3, 32.6\xb10.3, 33.8\xb10.3, 35.0\xb10.3, 35.6\xb10.3, 36.4\xb10.3, 37.6\xb10.3, and 38.0\xb10.3.
48. The crystalline form of lamivudine sulfate of any of claims 41-47, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine sulfate comprises at least 20 peaks with degrees 2\u03b8 values selected from the group consisting of 9.8\xb10.3, 10.3\xb10.3, 14.0\xb10.3, 14.5\xb10.3, 14.7\xb10.3, 15.4\xb10.3, 16.0\xb10.3, 16.4\xb10.3, 17.0\xb10.3, 19.0\xb10.3, 19.6\xb10.3, 20.2\xb10.3, 20.7\xb10.3, 21.4\xb10.3, 21.7\xb10.3, 22.5\xb10.3, 23.1\xb10.3, 24.1\xb10.3, 24.6\xb10.3, 24.9\xb10.3, 26.4\xb10.3, 27.0\xb10.3, 27.4\xb10.3, 27.9\xb10.3, 28.2\xb10.3, 29.5\xb10.3, 30.0\xb10.3, 30.3\xb10.3, 30.8\xb10.3, 31.8\xb10.3, 32.1\xb10.3, 32.6\xb10.3, 33.8\xb10.3, 35.0\xb10.3, 35.6\xb10.3, 36.4\xb10.3, 37.6\xb10.3, and 38.0\xb10.3.
49. The crystalline form of lamivudine sulfate of any of claims 41-48, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine sulfate comprises peaks with degrees 2\u03b8 values of 9.8\xb10.3, 10.3\xb10.3, 14.0\xb10.3, 14.5\xb10.3, 14.7\xb10.3, 15.4\xb10.3, 16.0\xb10.3, 16.4\xb10.3, 17.0\xb10.3, 19.0\xb10.3, 19.6\xb10.3, 20.2\xb10.3, 20.7\xb10.3, 21.4\xb10.3, 21.7\xb10.3, 22.5\xb10.3, 23.1\xb10.3, 24.1\xb10.3, 24.6\xb10.3, 24.9\xb10.3, 26.4\xb10.3, 27.0\xb10.3, 27.4\xb10.3, 27.9\xb10.3, 28.2\xb10.3, 29.5\xb10.3, 30.0\xb10.3, 30.3\xb10.3, 30.8\xb10.3, 31.8\xb10.3, 32.1\xb10.3, 32.6\xb10.3, 33.8\xb10.3, 35.0\xb10.3, 35.6\xb10.3, 36.4\xb10.3, 37.6\xb10.3, and 38.0\xb10.3.
50. The crystalline form of lamivudine sulfate of any of claims 41-49 having an X-ray powder diffraction pattern substantially the same as that shown in FIG. 15.
51. The crystalline form of lamivudine sulfate of any of claims 41-50, which exhibits a Raman spectrum comprising peaks at wave number values of about 700\xb15 and 977\xb15.
52. The crystalline form of lamivudine sulfate of claim 51, which exhibits a Raman spectrum further comprising peaks at wave number values of about 273\xb15, 410\xb15, 571\xb15, 601\xb15, 662\xb15, 1048\xb15, 1136\xb15, 1319\xb15, 1369\xb15, 1436\xb15, 1535\xb15, 1655\xb15, and 1715\xb15.
53. The crystalline form of lamivudine sulfate of any of claims 41-52, which exhibits a Differential Scanning Calorimetry thermogram comprising an endotherm with an onset of about 207.2\xb10.5\xb0 C. for a scan rate of about 10\xb0 C. per minute.
54. The crystalline form of lamivudine sulfate of any of claims 41-53, which exhibits a Differential Scanning Calorimetry thermogram having a single endotherm with an onset of about 207.2\xb10.5\xb0 C. for a scan rate of about 10\xb0 C. per minute.
55. The crystalline form of lamivudine sulfate of any of claims 41-54, which is neither hydrated nor solvated.
56. The crystalline form of lamivudine sulfate of any of claims 41-55, which is a hemi-sulfate, a mono-sulfate, or a di-sulfate.
57. The crystalline form of lamivudine sulfate of any of claims 41-56, which is a mono-sulfate.
58. A method of making a crystalline form of lamivudine sulfate of any of claims 41-57, comprising:
dissolving lamivudine in a solvent to form a solution;
adding sulfuric acid to the solution; and
optionally heating the solution to an elevated temperature.
59. The method of claim 58, further comprising, after heating the suspension:
cooling the solution to a cooling temperature.
60. The method of claim 59, wherein the steps of heating the suspension and cooling the suspension comprise repeating the heating and cooling steps for about 6 hours to about 24 hours.
61. The crystalline form of lamivudine sulfate of claim 41, wherein the crystalline form of lamivudine sulfate is lamivudine sulfate polymorph Form II.
62. The crystalline form of lamivudine sulfate of any of claim 41 or 61, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine sulfate comprises peaks with degrees 2\u03b8 values of 15.9\xb10.3, 20.1\xb10.3, and 24.8\xb10.3.
63. The crystalline form of lamivudine sulfate of claim 62, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine sulfate further comprises peaks with degrees 2\u03b8 values of 24.1\xb10.3 and 26.4\xb10.3.
64. The crystalline form of lamivudine sulfate of claim 63, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine sulfate further comprises peaks with degrees 2\u03b8 values of 20.6\xb10.3 and 21.6\xb10.3.
65. The crystalline form of lamivudine sulfate of any of claim 41 or 61-64, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine sulfate comprises at least five peaks with degrees 2\u03b8 values selected from the group consisting of 10.3\xb10.3, 12.1\xb10.3, 13.3\xb10.3, 14.0\xb10.3, 14.7\xb10.3, 15.4\xb10.3, 15.9\xb10.3, 17.0\xb10.3, 17.4\xb10.3, 18.7\xb10.3, 18.9\xb10.3, 19.6\xb10.3, 20.1\xb10.3, 20.5\xb10.3, 20.6\xb10.3, 21.3\xb10.3, 21.6\xb10.3, 22.5\xb10.3, 23.0\xb10.3, 23.6\xb10.3, 24.1\xb10.3, 24.8\xb10.3, 26.4\xb10.3, 26.9\xb10.3, 27.4\xb10.3, 28.2\xb10.3, 29.5\xb10.3, 30.0\xb10.3, 30.3\xb10.3, 30.8\xb10.3, 31.3\xb10.3, 32.6\xb10.3, 33.1\xb10.3, 34.0\xb10.3, 35.1\xb10.3, 35.5\xb10.3, 37.2\xb10.3, 37.6\xb10.3, and 38.4\xb10.3.
66. The crystalline form of lamivudine sulfate of any of claim 41 or 61-65, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine sulfate comprises at least 10 peaks with degrees 2\u03b8 values selected from the group consisting of 10.3\xb10.3, 12.1\xb10.3, 13.3\xb10.3, 14.0\xb10.3, 14.7\xb10.3, 15.4\xb10.3, 15.9\xb10.3, 17.0\xb10.3, 17.4\xb10.3, 18.7\xb10.3, 18.9\xb10.3, 19.6\xb10.3, 20.1\xb10.3, 20.5\xb10.3, 20.6\xb10.3, 21.3\xb10.3, 21.6\xb10.3, 22.5\xb10.3, 23.0\xb10.3, 23.6\xb10.3, 24.1\xb10.3, 24.8\xb10.3, 26.4\xb10.3, 26.9\xb10.3, 27.4\xb10.3, 28.2\xb10.3, 29.5\xb10.3, 30.0\xb10.3, 30.3\xb10.3, 30.8\xb10.3, 31.3\xb10.3, 32.6\xb10.3, 33.1\xb10.3, 34.0\xb10.3, 35.1\xb10.3, 35.5\xb10.3, 37.2\xb10.3, 37.6\xb10.3, and 38.4\xb10.3.
67. The crystalline form of lamivudine sulfate of any of claim 41 or 61-66, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine sulfate comprises at least 20 peaks with degrees 2\u03b8 values selected from the group consisting of 10.3\xb10.3, 12.1\xb10.3, 13.3\xb10.3, 14.0\xb10.3, 14.7\xb10.3, 15.4\xb10.3, 15.9\xb10.3, 17.0\xb10.3, 17.4\xb10.3, 18.7\xb10.3, 18.9\xb10.3, 19.6\xb10.3, 20.1\xb10.3, 20.5\xb10.3, 20.6\xb10.3, 21.3\xb10.3, 21.6\xb10.3, 22.5\xb10.3, 23.0\xb10.3, 23.6\xb10.3, 24.1\xb10.3, 24.8\xb10.3, 26.4\xb10.3, 26.9\xb10.3, 27.4\xb10.3, 28.2\xb10.3, 29.5\xb10.3, 30.0\xb10.3, 30.3\xb10.3, 30.8\xb10.3, 31.3\xb10.3, 32.6\xb10.3, 33.1\xb10.3, 34.0\xb10.3, 35.1\xb10.3, 35.5\xb10.3, 37.2\xb10.3, 37.6\xb10.3, and 38.4\xb10.3.
68. The crystalline form of lamivudine sulfate of any of claim 41 or 61-67, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine sulfate comprises peaks with degrees 2\u03b8 values of 10.3\xb10.3, 12.1\xb10.3, 13.3\xb10.3, 14.0\xb10.3, 14.7\xb10.3, 15.4\xb10.3, 15.9\xb10.3, 17.0\xb10.3, 17.4\xb10.3, 18.7\xb10.3, 18.9\xb10.3, 19.6\xb10.3, 20.1\xb10.3, 20.5\xb10.3, 20.6\xb10.3, 21.3\xb10.3, 21.6\xb10.3, 22.5\xb10.3, 23.0\xb10.3, 23.6\xb10.3, 24.1\xb10.3, 24.8\xb10.3, 26.4\xb10.3, 26.9\xb10.3, 27.4\xb10.3, 28.2\xb10.3, 29.5\xb10.3, 30.0\xb10.3, 30.3\xb10.3, 30.8\xb10.3, 31.3\xb10.3, 32.6\xb10.3, 33.1\xb10.3, 34.0\xb10.3, 35.1\xb10.3, 35.5\xb10.3, 37.2\xb10.3, 37.6\xb10.3, and 38.4\xb10.3.
69. The crystalline form of lamivudine sulfate of any of claim 41 or 61-68 having an X-ray powder diffraction pattern is substantially the same as that shown in FIG. 19.
70. The crystalline form of lamivudine sulfate of any of claim 41 or 61-69, which exhibits a Raman spectrum comprising peaks at wave numbers of about 977\xb15 and 1656\xb15.
71. The crystalline form of lamivudine sulfate of claim 70, which exhibits a Raman spectrum further comprising peaks at wave numbers of about 273\xb15, 410\xb15, 571\xb15, 601\xb15, 622\xb15, 1048\xb15, 1136\xb15, 1319\xb15, 1369\xb15, 1436\xb15, 1535\xb15, and 1715\xb15.
72. The crystalline form of lamivudine sulfate of any of claim 41 or 61-71, which exhibits a Differential Scanning Calorimetry thermogram comprising an endotherm with an onset of about 166.3\xb10.5\xb0 C. for a scan rate of 10\xb0 C. per minute.
73. The crystalline form of lamivudine sulfate of any of claim 41 or 61-72, which exhibits a Differential Scanning Calorimetry thermogram having a single endotherm with an onset of about 166.3\xb10.5\xb0 C. for a scan rate of 10\xb0 C. per minute.
74. The crystalline form of lamivudine sulfate of any of claim 41 or 61-73, which is neither a hydrate nor a solvate.
75. A method of making a crystalline form of lamivudine sulfate of any of claim 41 or 61-74 comprising:
suspending lamivudine in a non-solvent to form a suspension;
adding sulfuric acid to the suspension; and
optionally heating the suspension to an elevated temperature.
76. The method of claim 75, further comprising, after heating the suspension:
cooling the suspension to a cooling temperature.
77. The method of claim 76, wherein the steps of heating the suspension and cooling the suspension comprise repeating the heating and cooling steps for about 6 hours to about 24 hours.
78. A crystalline form of lamivudine phosphate.
79. The crystalline form of lamivudine phosphate of claim 78, wherein the crystalline form of lamivudine phosphate is lamivudine phosphate polymorph Form I.
80. The crystalline form of lamivudine phosphate of any of claims 78-79, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine phosphate comprises peaks with degrees 2\u03b8 values of 15.3\xb10.3, 25.0\xb10.3, and 26.1\xb10.3.
81. The crystalline form of lamivudine phosphate of claim 80, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine phosphate further comprising peaks with 2\u03b8 values of 29.1\xb10.3 and 37.5\xb10.3.
82. The crystalline form of lamivudine phosphate of any of claims 78-81, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine phosphate comprises at least five peaks with degrees 2\u03b8 values selected from the group consisting of 7.1\xb10.3, 9.8\xb10.3, 13.3\xb10.3, 14.7\xb10.3, 15.3\xb10.3, 16.7\xb10.3, 17.2\xb10.3, 17.7\xb10.3, 18.8\xb10.3, 20.4\xb10.3, 21.9\xb10.3, 22.5\xb10.3, 23.1\xb10.3, 24.2\xb10.3, 25.0\xb10.3, 26.1\xb10.3, 27.7\xb10.3, 28.2\xb10.3, 29.1\xb10.3, 29.7\xb10.3, 30.8\xb10.3, 31.5\xb10.3, 33.2\xb10.3, 34.1\xb10.3, 36.0\xb10.3, 37.5\xb10.3, and 39.0\xb10.3.
83. The crystalline form of lamivudine phosphate of any of claims 78-82, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine phosphate comprises at least 10 peaks with degrees 2\u03b8 values selected from the group consisting of 7.1\xb10.3, 9.8\xb10.3, 13.3\xb10.3, 14.7\xb10.3, 15.3\xb10.3, 16.7\xb10.3, 17.2\xb10.3, 17.7\xb10.3, 18.8\xb10.3, 20.4\xb10.3, 21.9\xb10.3, 22.5\xb10.3, 23.1\xb10.3, 24.2\xb10.3, 25.0\xb10.3, 26.1\xb10.3, 27.7\xb10.3, 28.2\xb10.3, 29.1\xb10.3, 29.7\xb10.3, 30.8\xb10.3, 31.5\xb10.3, 33.2\xb10.3, 34.1\xb10.3, 36.0\xb10.3, 37.5\xb10.3, and 39.0\xb10.3.
84. The crystalline form of lamivudine phosphate of any of claims 78-83, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine phosphate comprises at least 20 peaks with degrees 2\u03b8 values selected from the group consisting of 7.1\xb10.3, 9.8\xb10.3, 13.3\xb10.3, 14.7\xb10.3, 15.3\xb10.3, 16.7\xb10.3, 17.2\xb10.3, 17.7\xb10.3, 18.8\xb10.3, 20.4\xb10.3, 21.9\xb10.3, 22.5\xb10.3, 23.1\xb10.3, 24.2\xb10.3, 25.0\xb10.3, 26.1\xb10.3, 27.7\xb10.3, 28.2\xb10.3, 29.1\xb10.3, 29.7\xb10.3, 30.8\xb10.3, 31.5\xb10.3, 33.2\xb10.3, 34.1\xb10.3, 36.0\xb10.3, 37.5\xb10.3, and 39.0\xb10.3.
85. The crystalline form of lamivudine phosphate of any of claims 78-84, wherein the X-ray powder diffraction pattern of the crystalline form of lamivudine phosphate comprises peaks with degrees 2\u03b8 values of 7.1\xb10.3, 9.8\xb10.3, 13.3\xb10.3, 14.7\xb10.3, 15.3\xb10.3, 16.7\xb10.3, 17.2\xb10.3, 17.7\xb10.3, 18.8\xb10.3, 20.4\xb10.3, 21.9\xb10.3, 22.5\xb10.3, 23.1\xb10.3, 24.2\xb10.3, 25.0\xb10.3, 26.1\xb10.3, 27.7\xb10.3, 28.2\xb10.3, 29.1\xb10.3, 29.7\xb10.3, 30.8\xb10.3, 31.5\xb10.3, 33.2\xb10.3, 34.1\xb10.3, 36.0\xb10.3, 37.5\xb10.3, and 39.0\xb10.3.
86. The crystalline form of lamivudine phosphate of any of claims 78-85, having an X-ray powder diffraction pattern substantially the same as that shown in FIG. 23.
87. The crystalline form of lamivudine phosphate of any of claims 78-86, which exhibits a Raman spectrum comprising peaks at wave number of about 780\xb15 and 1652\xb15.
88. The crystalline form of lamivudine phosphate of claim 87, which exhibits a Raman spectrum further comprising peaks at wave number of about 353\xb15, 533\xb15, 562\xb15, 600\xb15, 709\xb15, 907\xb15, 971\xb15, 1054\xb15, 1367\xb15, 1444\xb15, 1535\xb15, and 1708\xb15.
89. The crystalline form of lamivudine phosphate of any of claims 78-88, which exhibits a Differential Scanning Calorimetry thermogram comprising an endotherm with an onset of about 167\xb10.5\xb0 C. for a scan rate of 10\xb0 C. per minute.
90. The crystalline form of lamivudine phosphate of any of claims 78-89, which exhibits a Differential Scanning Calorimetry thermogram having a single endotherm with an onset of about 167\xb10.5\xb0 C. for a scan rate of 10\xb0 C. per minute.
91. The crystalline form of lamivudine phosphate of any of claims 78-90, which is neither hydrated nor solvated.
92. A method of making a crystalline form of lamivudine phosphate of any of claims 78-91, comprising:
dissolving lamivudine in a solvent to form a solution;
adding phosphoric acid to the solution; and
optionally heating the solution to an elevated temperature.
93. The method of claim 92, wherein the phosphoric acid comprises orthophosphoric acid.
94. The method of any of claims 92-93, further comprising, after heating the solution:
cooling the solution to a cooling temperature.
95. The method of claim 94, wherein the steps of heating the suspension and cooling the suspension comprise repeating the heating and cooling steps for about 6 hours to about 24 hours.
96. A pharmaceutical composition comprising a crystalline form of a lamivudine salt of any of claims 1-30, 41-57, 61-74, 78-91, and one or more pharmaceutically acceptable ingredients.
97. A method of treating an HIV infection comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline form of a lamivudine salt of any of claims 1-30, 41-57, 61-74, 78-91 or a pharmaceutical composition of claim 96.
98. A method of treating a hepatitis B infection comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline form of a lamivudine salt of any of claims 1-30, 41-57, 61-74, 78-91 or a pharmaceutical composition of claim 96.
99. A method of treating a retrovirus infection comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline form of a lamivudine salt of any of claims 1-30, 41-57, 61-74, 78-91 or a pharmaceutical composition of claim 96.